FT819 for Lupus Nephritis

(RECLAIM-LN Trial)

This trial aims to test the effectiveness and safety of a new treatment called FT819 for individuals with lupus nephritis, a severe kidney condition linked to lupus. FT819 uses specially engineered T cells to target and potentially improve kidney function. Participants must have moderate-to-severe lupus nephritis that hasn't improved with at least two previous treatments. The study seeks to determine if FT819 can help achieve complete kidney response by week 26. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that FT819 is generally safe. In studies involving 59 patients with autoimmune conditions and cancer, the treatment caused few side effects. Importantly, no serious side effects or reactions halted further treatment. Patients did not experience cytokine release syndrome (a severe immune reaction) or neurotoxicity (nervous system damage). This suggests that FT819 is well-tolerated and safe for people.¹²³⁴⁵

Unlike the standard treatments for lupus nephritis, which typically include corticosteroids and immunosuppressive drugs, FT819 offers a novel approach by using allogeneic T cells. These T cells are derived from a clonal, TCR knockout iPSC line and are engineered to express a CD19-targeted CAR, regulated by the TRAC locus. This advanced mechanism allows FT819 to specifically target and potentially reduce the immune attack on the kidneys. Researchers are excited about FT819 because it represents a cutting-edge approach that could provide a more targeted and effective treatment option for lupus nephritis, potentially reducing the need for broad immunosuppression and its associated side effects.

Research has shown that FT819, a treatment using specially modified T cells, holds promise for people with lupus nephritis. In earlier studies, all patients treated with FT819 showed a noticeable decrease in disease activity. They also experienced significant reductions in protein levels in their urine, a positive sign for kidney health. Improvements in various health scores indicated better overall outcomes. This treatment targets CD19, a marker on certain immune cells, to help reduce inflammation and disease symptoms. Overall, FT819 has demonstrated a positive impact on kidney issues related to lupus.¹²⁵⁶⁷